Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications

Revista Espanola de Enfermedades Digestivas

Volumn 89, Issue 7, 1997, Pages 541-550

  Olaso, V ^a   Cordoba J ^a   Berenguer, M ^a   Prieto, M ^a   Lainez, B ^a   Arguello L ^b   Valverde, J ^a   Pascual, S ^a   Gobernado, M ^a   Berenguer, J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Hospital La Fe ^*

Author keywords

Chronic hepatitis C; Hepatitis C virus (HCV); Interferon

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA; ALPHA INTERFERON;

ADOLESCENT; ADULT; ARTICLE; CHRONIC HEPATITIS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; VIREMIA; VIRUS HEPATITIS; BIOPSY; COMPARATIVE STUDY; GENETIC TRANSCRIPTION; GENETICS; LIVER; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; TIME;

ADOLESCENT; ADULT; BIOPSY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 84866474045     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M, Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1089;244:359-62.
2. Choo Q-L, Weiner AJ, Overby LR, Kuo G, Houghton M, Bradley DW. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Mull 1990:46:423-41.
3. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotono K. Molecular cloning of the human hepatitis C genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990;87:9524-8.
4. Okamoto H, Okada S, Sugiyama Y, Kurai K, Iizuka H, Machida A, Miyakawa Y, et al. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier. J Gen Virol 1991;72:2697-704.
5. Takamizawa A, Mori C, Fuke Y, Manabe S, Murakami S, Fujita J, Onishi E, et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991;65:1105-13.
6. Alter HJ, Hadler SC, Judson FN, Mares A, Alexander WJ, Hu PY, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
7. Ikeda K, Saitoh S, Koida Y, Arase Y, Tsubota A, Chayama K, Kumada H, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
8. Hoofnagle HJ, Mullen KD, Jones DB, Rustgi V, DiBisceglie AM, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha Interferon. N Engl J Med 1986;315:1575-8.
9. DiBisceglie AM, Martin P, Kassiandies C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C. N Engl J Med 1989;321:1506-10.
10. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. New Engl J Med 1989;321:1506-10.
11. Marcellin P, Boyer N, Giostra E, Degotto C, Courouce AM, Degos F, Coppere H, et al. Recombinant human a-interferon in patients with chronic non-A, non-B hepatitis. Hepatology 1991;13:393-7.
12. Caussè X, Godinot H., Chevallier M, Chossengros P, Zoulim F, Ouzan D, Heyrand JP, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic nonA, non-B hepatitis. Gastroenterology 1991;101:497-502.
13. Tine F, Magrin S, Craxi A, Pagharo L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991;13:192-9.
14. Weiland O, Schwarcz R, Wejstal R, Norkrans G, Frydén A. Therapy of chronic posttransfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol 1990;11:S57-S62.
15. Realdi G, Diodati G, Bonetti P, Scaccabarozzi S, Alberti A, Ruol A. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial. J Hepatol 1990;11:S68-S71.
16. Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM, Thomas HC. Randomised controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J 1989;298:80-2.
17. Malaguarnera M, Restuccia S, Trovato G, Siciliano R, Motta M, Tovato BA. Interferon-α treatment in patients with chronic hepatitis C. A meta-analytic evaluation. Clin Drug Invest 1995;9:141-9.
18. Bardelli F, Messori A, Rampazzo R, Alberti A, Martini N. Effect of recombinant or lymphoblastoid interferon-α on alanine aminotransferase in patients with chronic hepatitis C or chronic non-A non-B hepatitis. Clin Drug Invest 1995;9:239-54.
19. Ravaggi A, Zonaro A, Mazza C, Albertini A, Cariani E. Quantification of Hepatitis C Virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates. J Clin Microbiol 1995;33:265-9.
20. Mantero, G., Zonaro A, Albertini A, Bertolo P, Primi D. DNA enzyme immunoassay: general method for detecting products of polymerase chain reaction. Clin. Chem 1991;37:422-9.
21. Ravaggi, A, Primi D, Cariani E. Direct PCR amplification of HCV RNA from human serum. PCR Methods Appl 1992;1:291-2.
22. Kwok S, Hisuchi R. Avoiding false positives with PCR. Nature 1989;339:237-8.
23. Imberti L, Cariani E, Bettinardi A, Zonaro A, Albertini A, Primi D. An immunoassay for specific amplified HCV sequences. J Virol Methods 1991;34:233-43.
24. Young K, Resnick R, Myers T. Detection of hepatitis C virus RNA by a combined reverse transcription polymerase chain reaction assay. J Clin Microb 1993;31:882-6.
25. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Va Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization new subtipes using a line probe assay. J Gen Virol 1993;74:1093-110.
26. Davis GL. Predictors of response to interferon treatment of chronic hepatitis C. J Hepatol 1994;21:1-3.
27. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperna A, Pozzi M, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995;21:645-9.
28. Okada S-I, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992;16:619-24.
29. Finkelstein SD, Sayegh R, Uchman S, Christensen S, Swalsky P. HCV undergoes extensive mutational change in NS5 region in association with relapse/breakthrough following alpha-interferon therapy. Hepatology 1992;16:132A (Abstract).
30. Marcellin P, Boyer N, Degott C, Martinot-Peignoux M, Duchatelle V, Giostra E, Areias J, et al. Long-term histologic and viral changes in patientes with chronic hepatitis C who responded to alpha interferon. Liver 1994;14:302-7.
31. De Alava E, Camps J, Pardo-Mindán J, García-Granero M, Muñoz M, Civeira SJ, Vázquez CF, et al Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon. Liver 1993;13:73-79.
32. 2b. A multicenter study. Dig Dis Sci 1993;38:612-8.
33. 2b for 60 weeks. Hepatology 1994;19:280-5.
34. Poynard T, Bedossa P, Chevallier M, Mathurin PH, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment fo chronic non-A, non-B hepatitis. New Engl J Med 1995;332:1457-62.
35. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 1995;21:291-7.
36. 2b. Hepatology 1993;18:1300-5.
37. 2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. J Hepatol 1995;23:487-96.
38. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimes of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-6.
39. Saracco G, Rosina F, Abate L, Carucci P, Solinas A, Chiandussi L, Bonino F, et al. Long term response to interferon-alfa 2b re-treatment in chronic hepatitis C. J Hepatol 1994;21:278-9.
40. Gerken G, Teuber G, Goergen B y Meyer zum Büschenfelde KH. Interferon-alpha retreatment in chronic hepatitis C. J Hepatol 1995;22(S1):118-21.
41. Kakumu S, Yoshioka K. Re-treatment with interferon in patients with chronic hepatitis C. J Hepatol 1994;21:483.
42. Cipriani-Giudici A, Azzola E, Varagona G, Vitali A, Marenco G, De Conca V, Mesiti G, et al. Usefulness of retreatment with interferon (IFN) in relapsing and non-responder patients with chronic hepatitis C. J Hepatol 1993;18:S123-S4 (Abstract).
43. Toyoda H, Nakano S, Takeda Y, Kumada T, Sugiyama K, Osada T, Kiriyama S, et al. Re-rreatment of crhonic hepatitis C with interferon. Am J Gastroenterol 1994;89:1453-7.
44. Marcellin P, Boyer N, Pouteau M, Benhamou JP, Erlinger S. Retreatmen with interferon-α of chronic hepatitis C virus infection. Lancet 1994;344:690-1.
45. Arase Y, Kumada H, Chayama K, Tsubota A, Koida Y, Ikeda K, Saitoh S, et al. J Gastroenterol 1994;29:299-304.
46. Negro F, Baldi M, Mondardini A, Leandro G, Chaneac M, Manzini P, Abate ML, et al. Continous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994;107:479-85.
47. Weiland O, Zhang Y-Y, Widell A. Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 1993;25:25-30.
48. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum HCV RNA levels and genotype are the main and independent prognostic of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
49. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase and response to interferon-α therapy: Relationship to genotipes of hepatitis C virus. Hepatology 1992;16:293-9.
50. Yoshioka K, Higashi Y, Yamada M, Aiyama T, Takayanagi M, Tanaka K, Okumura A, Iwata K, et al. Predictive factors in the response to interferomn therapy in chronic hepatitis C. Liver 1995;15:57-62.
51. Tsubota A, Ctayama K, Ikeda K, Yasuji A, Koida Y, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
52. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Kashiwagi S. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994;89:2151-6.
53. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
54. Lau JYN, Davis GL, Kniffen J, Quian K-P, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
55. Aiyama T, Yoshioka K, Hirofuji H, Kusakabe A, Yamada M, Tanaka K, Kakumu S. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1994;39:2244-9.
56. Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-β. Hepatology 1993;18:1319-25.
57. Aiyama T, Yoshioka K, Takayanagi M, Iwata K, Okumura A, Kakumu S. Serum RNA titer at the end of interferon therapy predicts the long-term outcome of treatment. J Hepatol 1995;23:497-502.
58. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K. Degree de diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 1994;20:1144-51.
59. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Rasahara A, Fusamoto H, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121-30.
60. 2b therapy in patients with chronic hepatitis C. Dig Dis Sci 1994;39:1273-80.
61. Bresters D, Cuypers HTM, Reesink HW, Mauser-Bunschoten EP, van den Berg HM, Schaasberg WP, Wilber JC, et al. Comparison of quantitative cDNA-PCR with the branched DNA hybridization assay for monitoring plasma hepatitis C virus RNA levels in haemophilia patients participatina in a controlled interferon trial. J Med Virol 1994;43:262-8.
62. Di Bisceglie AM, Hoofnagle JH. Therapy of chronic hepatitis C with alfa interferon: the answer? Or more questions? Hepatology 1991;13:601-3.
63. Serfaty L, Giral PH, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994;21:12-7.
64. Pagliario L, Craxí A, Cammaá C, Tiné F, Di Marco V, Lo Iacono O, Almasio P. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994;19:820-8.
65. Van Thiel DV, Friedlander L, Fagiuoli S, Wrigh HI, Irish W, Gavaler JS. Response to interferon a therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-5.
66. Giostra F, Francesconi R, Groff P, Manzin A, Solforosi L, Lari F, Ballardini G, et al. Wide fuctuation of plasmatic HCV genome levels in serial samples of patients before interferon (IFN) treatment. Hepatology 1995;22:341A (Abstract).
67. Bourlière M, Halfon Ph, Berthezene P, Khiri H, Portal Y, Wartelle C, Gerolami, et al. Spontaneus fluctuations of viral load in untreated patients with chronic hepatitis C. Hepatology 1995;22:341A (Abstract).
68. Gordon SC, Khan BA, Dmuchowski CE, Kodali VP, Silverman AL. The spontaneous fluctuation of viremia over time in untreated patients with chronic type C hepatitis. Hepatology 1995;22:341A (Abstract).
69. Enomoto N, Sato Ch, Kurosaki M, Marumo F, Hepatitis C virus after interferon treatmen has the variation in the hypervariable region of envelope 2 gene. J Hepatol 1994;20:252-61.
70. Enomoto N, Sakamoto N, Kurosaki M, Marumo F, Sato Ch. The hypervariable region of the HCV genome changes sequentially during the progresión of acute HCV infection to chronic hepatitis. J Hepatol 1993;17:415-6.
71. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato Ch. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 1994;75:1361-9.
72. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato Ch. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 1994;75:1361-9.
73. Hagiwara H, Hayashi N, Naito M, Mita E, Kasahara A, Fusamoto H, Kamada T. Replicative level of HCV determined by the competitive reverse transcription and polymerase chain reaction assay in various stages of chronic HCV infection. In: Nishioka K, Suzuki H, Mishiro S, Oda T, (eds) Viral hepatitis and liver disease. Springer-Verlag, Tokyo 1993:357-60.
74. Chu H-W, Dash S, Gerber MA. Genomic and replicative hepatitis C virus RNA sequences and histologic activity in chronic hepatitis C. Hum Pathol 1994;25:160-3.
75. Gordon SC, Kodali VP, Silverman AL, Dmuchowski CF, Urdea MS, Chan CS, Wilber JC. Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. Am J Gastroenterol 1994;89:1458-61.
76. Rumi MG, Parravicini ML, Donato MF, Soffredini F, Wilber JC, Chan CS, Newald P, et al. Pretreatment Quantitative serum HCV-RNA and long-term response to alfa interferon (IFN) in chronic hepatitis C. Hepatology 1993;18:89A (Abstract).
77. Yun ZB, Reichard O, Chen M, Lundeberg J, Norkrans G, Fryden A, Sönnerborg A, et al. Serum hepatitis C virus RNA levels in chronic hepatitis C - Importance for outcome of interferon alfa-2b treatment. Scand J Infect Dis 1994;26:263-70.
78. Zeuzem S, Franke A, Lee J-H, et al. Phylogenetic analisys of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996;24:1003-9.
79. Lau JYN, Davis GL, Prescott LE, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med 1996;124:868-76.
80. Toyoda H, Nakano S, Kumada T, Takeda Y, Sugiyama K, Osada T, Kiriyama S, et al. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-α therapy in chronic hepatitis C patients. J Med Virol 1996;48:3549.
81. Gretch D, Corey L, Wilson J, De la Rosa C, Willson R, Carithers R, Jr, Busch M, et al. Assessment of hepatitis C virus ARN levels by Quantitative competitive RNA polymerase chain reaction: Hight-titer viremia correlates with advanced stage of disease. J Infec Dis 1994;169:1219-25.